WuXi AppTec Co., Ltd. (603259.SS)
- Previous Close
41.60 - Open
41.38 - Bid 42.91 x --
- Ask 42.92 x --
- Day's Range
41.30 - 43.13 - 52 Week Range
41.17 - 93.56 - Volume
119,709,427 - Avg. Volume
96,603,059 - Market Cap (intraday)
121.888B - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
13.25 - EPS (TTM)
3.24 - Earnings Date Apr 25, 2024 - Apr 26, 2024
- Forward Dividend & Yield 0.89 (2.08%)
- Ex-Dividend Date Jun 14, 2023
- 1y Target Est
79.03
WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical testing services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
www.wuxiapptec.com41,116
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 603259.SS
Performance Overview: 603259.SS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 603259.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 603259.SS
Valuation Measures
Market Cap
121.89B
Enterprise Value
113.87B
Trailing P/E
13.25
Forward P/E
12.27
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.15
Price/Book (mrq)
2.28
Enterprise Value/Revenue
2.82
Enterprise Value/EBITDA
7.96
Financial Highlights
Profitability and Income Statement
Profit Margin
23.81%
Return on Assets (ttm)
9.95%
Return on Equity (ttm)
18.94%
Revenue (ttm)
40.34B
Net Income Avi to Common (ttm)
9.61B
Diluted EPS (ttm)
3.24
Balance Sheet and Cash Flow
Total Cash (mrq)
14.56B
Total Debt/Equity (mrq)
10.25%
Levered Free Cash Flow (ttm)
3.58B
Research Analysis: 603259.SS
Company Insights: 603259.SS
603259.SS does not have Company Insights